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Aims: To examine the safety and efﬁcacy of linagliptin in patients with type 2 diabetes mellitus (T2DM) and
coronary artery disease (CAD) using pooled data from the global clinical trials program.
Methods: Patient-level data were pooled from randomized, placebo-controlled clinical trials of linagliptin
(5 mg, monotherapy or combination therapy). Safety/efﬁcacy analyses were conducted for patients with CAD
and ≥12 and ≥24 weeks of treatment, respectively.
Results: The safety analysis included 19 trials (linagliptin, n = 451; placebo, n = 272) and the efﬁcacy analysis,
12 trials (linagliptin, n = 328; placebo, n = 198); mean (± standard deviation) exposure to study treatment
was 212 (144) days linagliptin and 245 (171) days placebo. Occurrence of cardiac adverse events (AEs) was
similar for linagliptin- and placebo-treated patients (9.1% and 9.2%, respectively); exposure-adjusted incidence
rates (per 100 patient-years) were 16.6 and 14.0, respectively. Overall incidence of AEs was numerically lower
with linagliptin than placebo. After 24 weeks, mean adjusted change (standard error) from baseline
glycosylated hemoglobin was−0.64% (0.04) with linagliptin vs. –0.08% (0.05) with placebo (P b .001).
Conclusions: This comprehensive pooled analysis showed that addition of linagliptin to treatment regimens of
patients with T2DM and CAD was not associated with an increased incidence of cardiac AEs, was well tolerated,
and was effective.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery disease (CAD) is a prevalent condition in patients
with type 2 diabetes mellitus (T2DM) (Go, Mozaffarian, Roger, et al.,
2014; Huxley, Barzi, & Woodward, 2006); compared with individualsMS, Astra-Zeneca, Roche, GSK,
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Inc. This is an open access article uwithout diabetes, patients with T2DM have a two- to fourfold
increased risk of cardiovascular (CV) disease (Beckman, Creager, &
Libby, 2002; Haffner, Lehto, Rönnemaa, Pyörälä, & Laakso, 1998; Preis,
Hwang, Coady, et al., 2009). For patients with T2DM, the presence of
CAD results in poorer clinical outcomes compared with those without
CAD (Beckman et al., 2002; Franco, Steyerberg, Hu, Mackenbach, &
Nusselder, 2007; Miettinen, Lehto, Salomaa, et al., 1998). The
pathophysiology of diabetic vascular disease is complex, and patients
with T2DM may also have additional risk factors which increase the
risk of atherosclerosis, including hypertension, dyslipidemia, obesity,
smoking and insulin resistance. The importance of controlling these
risk factors through medication and lifestyle changes is well
established (Beckman et al., 2002). In particular, the control of
hyperglycemia has been shown to reduce the risk of microvascular
endpoints. Data from the United Kingdom Prospective Diabetes Study
(UKPDS) demonstrated, over a 10-year follow-up period, that
intensive glycemic control was associated with a reduction ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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infarction (MI) and death from any cause (Holman, Paul, Bethel,
Matthews, & Neil, 2008). Similarly, in the Kumamoto study, intensive
glycemic control was shown to delay the onset and progression of
early diabetic microvascular complications after an 8-year follow-up
of Japanese patients with T2DM (Shichiri, Kishikawa, Ohkubo, &
Wake, 2000). In contrast, the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study was prematurely terminated following a
recommendation by the data and safety monitoring committee due to
a 22% relative increase in risk of mortality and a 38% relative increase
in CV death among patients receiving an intensive strategy to reduce
glycosylated hemoglobin (HbA1c) levels, compared with those
with a less stringent HbA1c target, although the groups did not
differ with respect to the composite outcome measure of non-fatal
MI, non-fatal stroke or CV death (in fact, non-fatal MI was signiﬁcantly
reduced) (Gerstein, Miller, Byington, et al., 2008). Subsequent
reports from the ACCORD Study Group on long-term effects,
following 3.7 years of intensive glucose lowering, include reports
on outcomes after 5 years of follow-up (Gerstein, Miller, Genuth, et
al., 2011) as well as 9-year outcomes (in the ACCORD International
Ongoing [ACCORDION] Study) (The ACCORD Study Group Writing
Committee, 2016), which demonstrated persistence of the original
ﬁndings, in addition to an attenuation of the overall mortality risk,
shown in ACCORDION.
However, the use of intensive glucose control showed no beneﬁt on
macrovascular events for patients with T2DM in the Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modiﬁed-Release
Controlled Evaluation (ADVANCE) study. Although intensive glucose
control was associated with a signiﬁcant 10% relative reduction in the
combined outcome of major macrovascular and microvascular events
during amedian5-year follow-upperiod, thiswasmainly as a result of a
21% relative reduction in the incidence of nephropathy (P = .006), with
no risk reduction in the incidence of major macrovascular events or
death from CV causes (Patel, MacMahon, Chalmers, et al., 2008). In the
extended follow-up of this trial (median, 5.4 years' post-trial
follow-up), intensive glucose control during the trial did not lead to
long-term beneﬁts with respect to mortality or macrovascular events
(Zoungas, Chalmers, Neal, et al., 2014). Similarly, a study of American
veteranswith T2DM, theVeteransAffairsDiabetes Trial (VADT), showed
no signiﬁcant effect of intensive glycemic control on the incidence of
major CV events or on the risk of death from any cause, after a median
follow-up period of 5.6 years (Duckworth, Abraira, Moritz, et al., 2009).
However, after extended follow-up of the VADT population to 9.8 years
after the start of the study, patients who received intensive glucose
control for the ﬁrst 5.6 years were found to have a signiﬁcant 17%
reduction of the primary endpoint of macrovascular disease but no
improvement in cardiovascular- or overall survival (Hayward, Reaven,
Wiitala, et al., 2015).
In addition to uncertainties about the effectiveness of tight
glycemic control in reducing the risk of macrovascular events, this
approach can be associated with an increased risk of severe
hypoglycemic episodes, which can offset some of the CV beneﬁts of
therapy (Boussageon, Bejan-Angoulvant, Saadatian-Elahi, et al., 2011;
Mannucci, Monami, Lamanna, Gori, & Marchionni, 2009). Subgroup
analyses of UKPDS, ACCORD, ADVANCE and VADT suggest that
patients with T2DM of shorter duration and without established CV
disease (CVD) are more likely to beneﬁt from intensive glycemic
control, compared with those having more established disease for
whom the risks might outweigh the potential CV beneﬁts of intensive
therapy (Skyler, Bergenstal, Bonow, et al., 2009).
Developing optimal treatment strategies in patients with T2DM
and CAD remains a challenge in this high-risk population, where
individuals often present with multiple risk factors, which substan-
tially increase the risk for morbidity and mortality (Turner, Millns,
Neil, et al., 1998). In view of the need for polypharmacy, frequent
hospitalization and the risk of potential side effects or contraindica-tions to some drugs, selecting the appropriate glucose-lowering
treatment for these patients is uniquely challenging. The latest
Diabetes Management Guidelines from the American Association of
Clinical Endocrinologists (AACE) (Garber, Abrahamson, Barzilay, et al.,
2016) and the joint Position Statement from the American Diabetes
Association (ADA) and the European Association for the Study of
Diabetes (EASD) (Inzucchi, Bergenstal, Buse, et al., 2015) recommend
a patient-centered approach to management, with treatment indi-
vidualized to take account of risk factors, including comorbid
conditions such as CAD. Current uncertainty about the long-term CV
safety of speciﬁc glucose-lowering drugs (Selvin, Bolen, Yeh, et al.,
2008), has led to the recommendation by the U.S. Food and Drug
Administration (U.S. FDA) that the CV risk is evaluated for all
compounds, except insulins, that are being developed as therapies
for T2DM (U.S. FDA, 2008). As a result, many trials have been designed
to assess the long-term CV outcomes of recently developed drugs for
the management of T2DM, and there remains a clinical need for
approaches to glycemic control that do not further increase CV risk
(Cavender, Steg, Smith, et al., 2015).
Linagliptin is a dipeptidyl-peptidase (DPP)-4 inhibitor approved
for the treatment of T2DM. The overall safety and tolerability of
linagliptin have been established in a large clinical trial program
and further demonstrated in a pooled analysis of 22 placebo-
controlled trials of linagliptin (Lehrke, Marx, Patel, et al., 2014). The
ﬁndings of this analysis supported previous ﬁndings of a low
incidence of AEs and good overall tolerability of linagliptin in a
broad range of patients with T2DM. The CV safety of linagliptin has
been evaluated in a comprehensive patient-level pooled analysis of
prospectively adjudicated CV events from the clinical trial program
(Rosenstock, Marx, Neubacher, et al., 2015). This analysis of 19 trials
of at least 12 weeks’ duration, in which linagliptin was evaluated in
comparison with placebo or one or more active comparators,
showed that linagliptin was not associated with increased CV risk
in patients with T2DM. A post-hoc pooled analysis of linagliptin as
add-on to insulin therapy in T2DM also demonstrated a neutral
effect of linagliptin on the occurrence of major CV AEs (Zinman
et al., 2016). Two CV outcome trials are underway with the aim of
further evaluating the CV safety of linagliptin. The CARdiovascular
Outcome Study of LINAgliptin versus Glimepiride in Patients with
Type 2 Diabetes (CAROLINA®) (NCT01243424) has randomized
6041 patients with early T2DM who are at high CV risk to receive
therapy with linagliptin or the sulfonylurea (SU) glimepiride
(Marx, Rosenstock, Kahn, et al., 2015; Rosenstock, Marx, Kahn,
et al., 2013). The CArdiovascular and Renal Microvascular OutcomE
Study With LINAgliptin in Patients With Type 2 Diabetes Mellitus
(CARMELINA®) (NCT01897532) trial will compare the CV and
renal safety of linagliptin vs. placebo, added to standard care in
patients with T2DM who are at high risk of vascular complications.
While the outcomes of dedicated CV safety trials of linagliptin are
awaited, analysis of available data from completed clinical trials
can provide some insights into the role of this agent in patients
with CAD or at high risk of CV events. The aim of this analysis was
to examine the safety and efﬁcacy of linagliptin in patients with
CAD using pooled data from a global clinical trials program.
2. Materials and methods
Patient-level data were pooled for this analysis from randomized,
placebo-controlled clinical trials of linagliptin 5 mg, of at least
12 weeks’ duration. The trials included linagliptin administered either
as monotherapy or in combination with other glucose-lowering
drugs. All trials were conducted in accordance with Good Clinical
Practice guidelines and the principles of the Declaration of Helsinki.
Eligibility criteria across the included trials were similar and included
a diagnosis of T2DM, age ≥18 years, HbA1c 7%–10% entrance criterion
in most studies, and a body mass index (BMI) of 20–45 kg/m2. In all
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tion in glycemic control. In general, rescue therapy was initiated if
glucose levels exceeded 240, 200 or 180 mg/dl (after an overnight
fast) on two separate days during the ﬁrst 12, 12–24 or N24 weeks,
respectively. Data collected after initiation of rescue therapy were
included in the analysis.
Patients with CAD were identiﬁed using relevant cardiac terms
from the standardized Medical Dictionary for Regulatory Activities
version 16.0 (MedDRA, v16.0) query “embolic and thrombotic
events”. Included terms were: acute coronary syndrome; acute
myocardial infarction; angina pectoris; angina unstable; arterioscle-
rosis coronary artery; arteriospasm coronary; coronary angioplasty;
coronary arterial stent insertion; coronary artery bypass; coronary
artery dilatation; coronary artery disease; coronary artery insufﬁ-
ciency; coronary artery occlusion; coronary artery stenosis; coronary
revascularization; microvascular coronary artery disease; myocardial
infarction; myocardial ischemia; percutaneous coronary intervention;
post procedural myocardial infarction; postinfarction angina; Prinz-
metal angina; silent myocardial infarction.
Safety analyses were conducted on patients who had at least
12 weeks of treatment and who had received at least one dose of
study drug (treated set). Data on AEs were collected by the study
investigators using electronic case report forms. The incidence and
intensity of AEs, including cardiac and hypoglycemic events, were
coded using MedDRA v16.0 and analyzed using descriptive statistical
methods. Data on investigator-reported cardiac AEs were deﬁned by
the MedDRA System Organ Class of “cardiac disorders” based on
clinical interpretation. Exposure-adjusted incidence rates were
calculated using the number of patients with the respective events
per treatment divided by the time at risk, expressed as 100
patient-years. Heart failure data were calculated as a total of the
narrow standardized MedDRA queries (SMQ), and consisted of the
following terms: acute left ventricular failure; acute pulmonary
edema; acute right ventricular failure; cardiac asthma; cardiac failure;
cardiac failure, acute; cardiac failure, chronic; cardiac failure,
congestive; cardiac failure, high output; cardiogenic shock; cardio-
pulmonary failure cardiorenal syndrome; chronic left ventricular
failure; chronic right ventricular failure; cor pulmonale; cor pulmo-
nale, acute; cor pulmonale, chronic; ejection fraction decreased;
hepatic congestion; hepatojugular reﬂux; left ventricular failure; low
cardiac output syndrome; neonatal cardiac failure; pulmonary edema;
pulmonary edema, neonatal; right ventricular failure; ventricular
failure. Reporting of AEs was also analyzed according to concomitant
use of insulin and/or SU therapy.
Overall hypoglycemic events included both asymptomatic and
symptomatic hypoglycemic events. In general, asymptomatic hypo-
glycemiawas deﬁned as an event that was not accompanied by typical
symptoms of hypoglycemia but with a measured plasma glucose
concentration ≤70 mg/dl (3.9 mmol/l). Symptomatic hypoglycemia
was deﬁned as a measured plasma glucose concentration ≥54 mg/dl
and ≤70 mg/dl (≥3.0 mmol/l and ≤3.9 mmol/l), accompanied by
typical symptoms of hypoglycemia, or symptomatic hypoglycemia
with a measured plasma glucose concentration b54 mg/dl
(b3.0 mmol/l): event accompanied by typical symptoms of hypogly-
cemia but no need for external assistance. A severe hypoglycemic
episode was deﬁned as an event requiring the assistance of another
person to actively administer carbohydrate, glucagon or other
resuscitative actions.
Efﬁcacy analyses were conducted using data from patients who
had received at least 24 weeks of treatment and at least one dose of
study drug at the 5-mg dosage, and who also had an HbA1c value at
baseline and at least one on-treatment value (full analysis set). The
change from baseline glycemic parameters for linagliptin and placebo
groups was compared using an analysis of covariance (ANCOVA). The
model included treatment, washout, study, and continuous baseline
HbA1c (HbA1c analysis) and baseline HbA1c and baseline fastingplasma glucose (FPG) (FPG analysis). The analysis used the last
observation carried forward (LOCF) method to assign values to
missing data. ANCOVA and logistic regression techniques were
applied to assess all continuous and categorical secondary and safety
endpoints, respectively.
3. Results
The safety analysis included patients from 19 trials (linagliptin,
n = 451; placebo, n = 272) (Supplementary Table 1). The mean
[±standarddeviation (SD)] exposure to study treatmentwas212 (144)
days in the linagliptin group and 245 (171) days for patients allocated to
placebo. Baseline characteristics, including the presence of CV risk
factors and use of non-study drugs for CV indications, were well
matched between the treatment groups (Table 1). Similar proportions
of patientswere receivingnone, oneormore than twoglucose-lowering
drugs. However, there were modest differences in the composition of
classes of drugs used, i.e., use of concomitant insulin (± other
glucose-lowering drugs), SU (± other glucose-lowering drugs) or
insulin + SU (Table 1).
Cardiac AEs were reported by 9.1% of patients in the linagliptin
group and 9.2% in the placebo group (Fig. 1A; Table 2). Exposure
adjusted incidence rates (per 100 patient-years) of cardiac AEs were
16.6 for linagliptin and 14.0 for placebo. The proportion of patients
reporting cardiac AEs was higher among those receiving concomitant
SU and/or insulin (linagliptin, 11.9%; placebo, 11.3%) compared with
patients not receiving these drugs (linagliptin, 2.8%; placebo, 2.9%)
(Fig. 1B).
The overall incidence of AEs was numerically lower with
linagliptin than placebo (Supplementary Table 2). In the linagliptin
group, the proportion of patients with any AE was higher among
patients receiving concomitant SU and/or insulin compared with
patients who were not receiving these drugs (73.2% vs. 47.5%);
corresponding values in the placebo group were 77.0% vs. 70.6%
(Table 3). The overall occurrence of investigator-reported events that
were suggestive of congestive heart failure (CHF) was low for
linagliptin- and placebo-treated patients, but higher among patients
on SU and/or insulin background therapy (Table 3). Similarly, among
linagliptin-treated patients, the proportion of patients with
investigator-reported hypoglycemia was greater among those receiv-
ing concomitant SU and/or insulin compared with patients who were
not taking these treatments (29.4% vs. 2.1%); corresponding values
were 32.8% and 0% in the placebo group (Supplementary Table 3).
Overall, the rates of exposure-adjusted investigator-reported hypo-
glycemia were slightly lower with linagliptin than with placebo
(Fig. 2).
The efﬁcacy analysis included patients from 12 trials (linagliptin,
n = 328; placebo, n = 198). The analysis demonstrated a signiﬁ-
cantly greater reduction in HbA1c among patients receiving linaglip-
tin vs. placebo: after 24 weeks of treatment themean adjusted change
(± standard error) from baseline HbA1c was −0.65% (±0.04) for
linagliptin-treated patients compared with −0.08% (±0.05) for the
placebo group (P b .001) (Supplementary Table 4). Patients were
more likely to achieve HbA1c lowering to b7% with linagliptin vs.
placebo (odds ratio 3.70; P b .0001).
4. Discussion
The results from this comprehensive pooled analysis show that the
addition of linagliptin to the treatment regimens of patients with a
previous history of CAD was well tolerated, with no changes to the
known safety proﬁle listed in the current prescribing information
(Boehringer Ingelheim Pharmaceuticals, 2015). Thus, the ﬁndings, in
patients with a pre-existing diagnosis of CAD and at high risk for
further CV events, are consistent with those of previous pooled
analyses of double-blind, randomized, controlled trials of lower risk
Table 1
Patient demographics and clinical characteristics at baseline (treated set).
Linagliptin 5 mg
(n = 451)
Placebo
(n = 272)
Age (years) 64.8 (9.1) 64.6 (9.3)
Sex (% male) 62.7 65.8
Body weight (kg) 84.4 (17.4) 87.4 (16.2)
Body mass index (kg/m2) 30.4 (4.9) 31.0 (4.8)
Race (%)
White 77.8 78.3
Asian 16.0 10.7
Black/African American 2.7 4.4
Other 0.4 1.1
Missing 3.1 5.5
Smoking status (%)
Never smoked 51.7 47.8
Ex-smoker 35.0 38.2
Current smoker 13.3 14.0
Alcohol status (%)
Drinker 37.9 36.8
HbA1c a (%) 8.1 (0.9) 8.1 (0.9)
b7.0% 6.2 6.3
7.0% to b8.0% 39.0 44.5
8.0% to b9.0% 35.3 30.5
≥9.0% 19.3 18.8
Fasting plasma glucose a, mg/dl 162.7 (46.7) 159.6 (46.7)
Renal function (eGFR) according to MDRD (%)
Normal or mild impairment (60 to ≥90 ml/min/1.73 m2) 71.2 66.5
Moderate or severe impairment, or ESRD (b30 to b60 ml/min/1.73 m2) 28.8 33.5
Systolic blood pressure (mmHg) 135.2 (15.8) 135.9 (16.8)
Pulse rate (bpm) 70.2 (10.5) 69.9 (10.5)
Lipids a (mg/dl)
Total cholesterol 178.9 (49.6) 173.1 (41.2)
Triglyceride 178.5 (108.7) 173.4 (120.5)
High-density lipoprotein 44.0 (11.7) 43.1 (11.0)
Low-density lipoprotein 100.2 (41.6) 97.2 (34.2)
Time since diagnosis of T2DM (%)
≤1 year 5.8 4.8
N1 to 5 years 23.3 17.6
N5 years 71.0 77.6
Glucose-lowering drugs (%)
0 10.2 6.6
1 38.4 43.8
≥2 51.4 49.6
Insulin ± other glucose-lowering drugs, excluding SU 31.0 52.6
SU ± other glucose-lowering drugs, excluding insulin 36.8 21.7
Insulin + SU ± other glucose-lowering drugs 1.1 0.7
Cardiovascular drugs (non-study) (%)
Aspirin 74.9 77.6
Antihypertensives 92.9 87.1
Statins 62.3 67.6
Peripheral artery disease (%) 11.3 13.6
Cerebrovascular disease (%) 11.1 12.5
Myocardial infarction (%) 30.4 32.4
Data are mean (SD) unless stated otherwise.
eGFR, estimated glomerular ﬁltration rate; MDRD, modiﬁcation of diet in renal disease; ESRD, end-stage renal disease.
a The number of patients with data available for these parameters is as follows. HbA1c: linagliptin n = 450, placebo n = 272; fasting plasma glucose: linagliptin n = 445, placebo
n = 269; total cholesterol: linagliptin n = 372, placebo n = 242; triglyceride: linagliptin n = 371, placebo n = 242; high-density lipoprotein: linagliptin n = 370, placebo n = 242;
low-density lipoprotein: linagliptin n = 371, placebo n = 239.
1381M. Lehrke et al. / Journal of Diabetes and Its Complications 30 (2016) 1378–1384populations that have evaluated safety data from the linagliptin global
clinical trials program (Lehrke et al., 2014; Rosenstock et al., 2015;
Schernthaner et al., 2014).
A key ﬁnding relative to the high-risk CAD patients that were the
focus of this analysis was that the overall incidence of cardiac AEs was
similar for patients receiving linagliptin and placebo (9.1% vs. 9.2%,
respectively). The exposure-adjusted incidence rate (per 100
patient-years), which allows for possible differences in follow-up
duration between treatment groups, also indicated that the incidence
of cardiac AEs was similar among linagliptin- vs. placebo-treated
patients (16.6% vs. 14.0%, respectively).
Given the potential inﬂuence of background medication on AE
rates, the occurrence of AEs was speciﬁcally investigated with regard
to patients receiving SU and insulin. We found that the proportion ofpatients who reported cardiac AEs with linagliptin was numerically
greater among patients treated with concomitant SU and/or insulin
compared with patients who were not receiving these drugs. As with
cardiac AEs, the overall rate of AEs with linagliptin was higher with
concomitant SU and/or insulin therapy than without. One obvious
explanation for this difference might be the presence of more
advanced T2DM among patients who required additional SU and/or
insulin to achieve glycemic control, and hence the presence of a
greater number of comorbidities in these patients than in those who
do not require SU and/or insulin. Previous studies have shown
linagliptin to be generally well toleratedwhen used as add-on therapy
to SU and/or insulin (Barnett et al., 2013; McGill, Barnett, Lewin, et al.,
2014; McGill, Sloan, Newman, et al., 2012; Yki-Järvinen, Rosenstock,
Durán-Garcia, et al., 2013).
Table 3
Any AEs and heart failure AEs by concomitant use of SU and/or insulin during screening.
Linagliptin 5 mg (n = 451) Placebo (n = 272)
Any AE
Concomitant SU/insulin
Patients analyzed, n 310 204
SU/insulin: yes (%) 73.2 77.0
Patients analyzed, n 141 68
SU/insulin: no (%) 47.5 70.6
Narrow SMQ heart failure
Concomitant SU/insulin
Patients analyzed, n 310 204
SU/insulin: yes (%) 2.6 1.5
Patients analyzed, n 141 68
SU/insulin: no (%) 0.7 0
Linagliptin (n=451)A
B
20
15
10
5
0
15
10
5
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incidence rateb
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Placebo (n=272)
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2.8 2.9
Fig. 1. Investigator-reported cardiac AEs a for the treated set (A), and by use of
concomitant SU/insulin (B). a Data are unadjudicated; deﬁned by the MedDRA System
Organ Class “cardiac disorders”. b Exposure-adjusted incidence rates are calculated
using the number of patients with the respective events per treatment divided by the
time at risk expressed as 100 patient-years. MedDRA v 16.0 used for reporting.
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mia with linagliptin therapy, both alone and when used in combination
with other glucose-lowering agents (Del Prato et al., 2011; Inagaki,
Watada, Murai, et al., 2013; Owens, Swallow, Dugi, & Woerle, 2011;
Taskinen, Rosenstock, Tamminen, et al., 2011). In this study, rates of
hypoglycemia with linagliptin were low and comparable with prior
pooled analyses, with slightly fewer hypoglycemic episodes reported in
the linagliptin group vs. placebo. Of course, this ﬁnding could be a
consequence of differences in background therapies — there was more
insulin use in the placebo group, although conversely there was also
greater SU use in the linagliptin group.Table 2
Investigator-reported cardiac AES by preferred term a (treated set).
Linagliptin 5 mg (n = 451)
% Incidence rate/100 p
Cardiac AEs 9.1 16.6
Acute myocardial infarction 0.7 1.1
Angina pectoris 2.0 3.4
Atrial ﬁbrillation 1.3 2.3
Cardiac failure c 0.4 0.8
Congestive cardiac failure c 0.7 1.1
Coronary artery disease 0.9 1.5
Left ventricular failure 0.7 1.1
Myocardial ischemia 0.9 1.5
Palpitations 0.4 0.8
Tachycardia 0.7 1.1
Narrow SMQ cardiac failured 2.0 3.4
MedDRA v 16.0 used for reporting.
SMQ, standardized MedDRA query.
a Data are unadjudicated; deﬁned by the MedDRA System Organ Class “cardiac disorders
b Exposure-adjusted incidence rates are calculated using the number of patients with
patient-years.
c Cardiac failure and congestive cardiac failure AEs are separate terms derived from the s
d Based on reported preferred terms.The improvements in glucose control in this vulnerable population
were consistent with previously reported data for the general
T2DM population (Del Prato et al., 2011; Owens et al., 2011; Taskinen
et al., 2011).
Several longer term studies designed to evaluate the CV safety of
other DPP-4 inhibitors have reported results: SAVOR-TIMI 53
(Saxagliptin Assessment of Vascular Outcomes Recorded in Patients
with Diabetes Mellitus—Thrombolysis in Myocardial Infarction 53
trial) (Scirica, Bhatt, Braunwald, et al., 2013), EXAMINE (EXamination
of cArdiovascular outcoMes with alogliptIN versus standard of carE in
patients with diabetes mellitus and acute coronary syndrome)
(White, Cannon, Heller, et al., 2013) and TECOS (Trial Evaluating
Cardiovascular Outcomes with Sitagliptin) (Green, Bethel, Armstrong,
et al., 2015). All of these placebo-controlled trials have demonstrated
a neutral effect of these agents (saxagliptin, alogliptin and sitagliptin,
respectively) on composite CV outcomes [CV death, stroke and
myocardial infarction (MI) in SAVOR and EXAMINE, and CV death,
stroke, MI and hospitalization for unstable angina in TECOS] in
patients with high risk for CV events (Scirica et al., 2013; White et al.,
2013). However, in SAVOR-TIMI 53, a statistically signiﬁcant
increased risk of hospitalization for CHF was associated with
saxagliptin therapy compared with the placebo group [3.5% vs. 2.8%,
respectively; HR, 1.27 (95% CI, 1.07 to 1.51; P = .007)] (Scirica et al.,
2013). Further evaluation of the EXAMINE data has shown no increase
in the risk of heart failure outcomes associated with alogliptin therapyPlacebo (n = 272)
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Fig. 2. Rate of exposure-adjusted investigator-reported hypoglycemia (treated set). a Asymptomatic or symptomatic hypoglycemia reported as AE. b Severe hypoglycemia is a
hypoglycemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions. c Symptomatic hypoglycemia is an AE
reported as a hypoglycemic event with typical symptoms of hypoglycemia. PG, plasma glucose.
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been published from the TECOS study, which evaluated sitagliptin in
patients with T2DM and established CVD (Green et al., 2015). In this
large study, sitagliptin was found to be associated with no increase in
the risk of major adverse CV events [sitagliptin was noninferior to
placebo for the composite outcome of CV death, non-fatal MI,
non-fatal stroke or hospitalization for unstable angina; HR, 0.98
(95% CI, 0.88 to 1.09; P b .001)] or hospitalization for heart failure
[HR, 1.00 (95% CI, 0.83 to 1.20; P = .98)] (Green et al., 2015). A recent
retrospective, observational study, using information from aUS insurance
claims database, found no association between hospitalization for heart
failure and treatment with a DPP-4 inhibitor relative to SU therapy, or
treatment with saxagliptin relative to sitagliptin (Fu, Johnston, Ghannam,
et al., 2016). At present, therefore, it remains unclear whether the
observation of an increase in hospitalization for CHF with saxagliptin
(Scirica et al., 2013) was an adverse effect of this speciﬁc therapy or a
chance ﬁnding.
For linagliptin, where there are currently no published CV
outcomes data, the aforementioned pooled analyses of linagliptin
trial data provide the best indication of CV safety. This pooled analysis
also showed that the occurrence of investigator-reported events that
were suggestive of CHF was low for linagliptin- and placebo-treated
patients [0.5% (26 events), 0.2% (8 events)] (Rosenstock et al., 2015).
In the current analysis, which evaluated linagliptin in patients with a
pre-existing diagnosis of CAD and, therefore, at high risk for further
CV events, the incidence of reported cardiac AEs (per 100
patient-years) was comparable (16.6 for linagliptin and 14.0 for
placebo) with those of the previous pooled analyses of linagliptin
(Lehrke et al., 2014; Rosenstock et al., 2015). Further understanding of
the CV safety of linagliptin will be provided by the results of the
ongoing CAROLINA® and CARMELINA® trials.
The present analysis has several limitations because of its pooled
design and the small number of patients with T2DM and CAD
available for inclusion in the analysis. Further limitations are the
relatively short and differing durations of the included studies, the fact
that none of the individual studies included in this analysis were
powered or designed to assess CV risk or events, and that there was no
randomization procedure in this analysis for the patients that were
identiﬁedwith CAD. In addition, themean individual patient exposure
to linagliptin and placebo was less than 1 year (212 days and
245 days, respectively) and, therefore, no conclusions on the
long-term CV safety of linagliptin can be drawn.
In summary, and despite the limitations of this pooled analysis, the
ﬁnding that linagliptin is not associated with an increase in CV risk inpatients with T2DM and CAD will be reassuring to clinicians. The
results of CAROLINA® and CARMELINA® and other ongoing trials of
the CV safety of glucose-lowering therapies will further assist
clinicians in their efforts to optimize treatment strategies for patients
with or at risk of CVD and T2DM.Acknowledgments
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